Casdin Capital’s Contineum Therapeutics CTNM Stock Holding History

Casdin Capital’s Portfolio CTNM Stock Details CTNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.43M	Hold	148,333	–	–	0.12%	36
2026 Q1	$1.94M	Hold	148,333	–	–	0.15%	36
2025 Q4	$1.7M	Hold	148,333	–	–	0.11%	33
2025 Q3	$1.74M	Hold	148,333	–	–	0.15%	26
2025 Q2	$589K	Hold	148,333	–	–	0.05%	30
2025 Q1	$1.04M	Sell	148,333 -148,333	-50%	-$1.35M	0.08%	37
2024 Q4	$4.35M	Hold	296,666	–	–	0.29%	31
2024 Q3	$5.68M	Hold	296,666	–	–	0.38%	26
2024 Q2	$5.22M	Buy	+296,666	New	+$4.78M	0.4%	26

Other funds holding CTNM

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Casdin Capital's CTNM Position: Q2 2026 in Review

Casdin Capital held its Contineum Therapeutics (CTNM) position steady in Q2 2026 at 148,333 shares worth $2.43M. The position accounts for 0.12% of the portfolio, ranked #36.

Casdin Capital first reported a position in CTNM in Q2 2024 and has held it in 9 quarters since. The position peaked at $5.68M in Q3 2024. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

Casdin Capital held 148,333 shares of Contineum Therapeutics worth $2.43M as of Q2 2026.
Casdin Capital left its Contineum Therapeutics share count unchanged in Q2 2026.
Contineum Therapeutics made up 0.12% of Casdin Capital's portfolio in Q2 2026, its #36 holding.
Casdin Capital first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 9 quarters since.
Casdin Capital's Contineum Therapeutics position peaked at $5.68M in Q3 2024.
102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Casdin Capital's 13F filing for Q2 2026, filed 14 Aug 2026.